CEO Executive AssistantRegulatory submissions are the defining milestone events in a pharmaceutical company’s lifecycle. An NDA or BLA submission is the culmination of years of research, hundreds of millions in investment, and the combined effort of regulatory affairs, clinical, manufacturing, and medical writing teams. The CEO’s role in navigating these submissions is strategic: ensuring the organization is aligned, resourcing the submission team appropriately, managing the board and investor communications that surround major regulatory milestones, and engaging with FDA or global agency leadership at the right moments.
What the CEO should not be doing is managing the administrative logistics of that coordination. Regulatory submission timelines involve hundreds of interdependent tasks across multiple teams, months-long documentation production cycles, and stakeholder communications that require coordination across regulatory affairs, legal, commercial, and investor relations. When the CEO gets pulled into the logistics, both the CEO’s strategic function and the submission process suffer.
An executive assistant who is trained to coordinate regulatory submission administration gives the pharmaceutical CEO the visibility and bandwidth to lead the submission strategically without being consumed by it.
Understanding the Regulatory Submission Landscape
Submission Types and Their Administrative Requirements
Pharmaceutical regulatory submissions take multiple forms: New Drug Applications (NDAs), Biologics License Applications (BLAs), supplemental applications for label expansions, Investigational New Drug applications (INDs), and global equivalent submissions for EMA and other regulatory bodies. Each type has different administrative requirements, different timelines, and different levels of CEO involvement.
The EA’s role is not to understand the scientific or regulatory content of these submissions but to understand their administrative structure: when key milestones occur, who is responsible for each component, what the critical path is, and where CEO attention is needed. The EA maintains this map for every submission in progress and surfaces CEO-relevant information on the appropriate schedule.
The CEO’s Strategic Submission Role
In a well-run pharmaceutical company, the CEO’s direct submission involvement is limited to specific decision points: resource allocation, go/no-go decisions on submission timing, agency meeting strategy, and board and investor communication. The EA coordinates the administrative support for each of these touch points so the CEO can engage at the strategic level without needing to track the operational details between engagements.
Submission Timeline Tracking
Building the Master Submission Calendar
The EA maintains a master regulatory submission calendar that covers every active submission across all programs and all markets. This calendar shows current submission status, key upcoming milestones (submission date targets, PDUFA dates, FDA meeting dates, Complete Response Letter deadlines), and any status changes that have occurred since the last update.
This calendar is updated on a regular cadence (typically monthly, or more frequently during active submission periods) with inputs from the regulatory affairs team. The EA reviews it in advance of every regulatory-related CEO meeting and prepares a summary that highlights what has changed and what decisions are approaching.
For a multi-program pharmaceutical company, this calendar may track 10 to 30 or more submission-related events across a rolling 12-month period. Without a dedicated coordination system, the CEO risks losing visibility on approaching deadlines until they are upon the team.
Critical Path Monitoring
Every regulatory submission has a critical path: the sequence of tasks whose delay directly delays the submission date. The EA works with the regulatory project manager to understand what is on the critical path for each active submission and flags critical path risks to the CEO when they arise.
This is not duplicating the project management function. It is providing the CEO with an early warning system for situations that may require executive intervention: resource conflicts, manufacturing hold-ups, or data issues that threaten the submission timeline. A CEO who hears about a critical path risk three months out has options. A CEO who hears about it three weeks out has a crisis.
FDA and Regulatory Agency Meeting Coordination
Type A, B, and C Meeting Administration
Pharmaceutical companies engage with the FDA through a structured meeting protocol that includes Type A meetings (dispute resolution), Type B meetings (pre-IND, end-of-Phase 2, pre-NDA/BLA), and Type C meetings (all other). These meetings are strategic events: the questions asked and positions taken can shape regulatory strategy for years.
The EA coordinates all administrative aspects of these meetings: managing the meeting request submission process, tracking FDA response deadlines (30 days for Type A, 70 days for Type B, 90 days for Type C), coordinating the preparation of the meeting package, and managing internal alignment meetings in advance of the FDA interaction.
For the CEO who participates in FDA meetings, the EA prepares a meeting briefing: the questions being submitted, FDA’s typical positions on the relevant issues, the company’s desired outcomes, and any background on the specific review division and reviewer relationships.
Pre-Meeting Internal Preparation
High-stakes agency meetings require significant internal preparation. The EA coordinates this preparation process: scheduling pre-meeting planning sessions with regulatory affairs, clinical, and legal leadership, tracking the development of response scenarios to anticipated FDA questions, arranging mock meeting sessions when appropriate, and ensuring the CEO has reviewed and approved the final position on each key issue before the meeting.
This coordination function is time-consuming and detail-intensive. Without dedicated EA support, it often falls to the regulatory affairs team, whose bandwidth is better spent on the substantive preparation rather than the logistics.
Submission Team Coordination Support
Cross-Functional Submission Meetings
Regulatory submissions require sustained coordination across regulatory affairs, medical writing, data management, biostatistics, manufacturing, quality, and commercial teams. The CEO typically does not attend the working-level submission meetings but does attend submission governance meetings where cross-functional progress is reviewed and escalations are resolved.
The EA manages the CEO’s involvement in this governance structure: scheduling and preparing for submission governance meetings, compiling status reports from team leads for CEO review, capturing and tracking action items from governance meetings, and flagging escalations that require CEO intervention.
This governance coordination function ensures the CEO has a structured cadence of submission oversight without requiring immersion in daily working-team logistics.
External Regulatory Counsel Coordination
Many pharmaceutical companies engage external regulatory counsel for submissions: law firms or regulatory consulting firms that provide strategic advice, write specific sections, or review the full package. The EA coordinates the administrative relationship with these external partners: scheduling review meetings, managing document exchange logistics, tracking deliverable timelines, and organizing the billing and engagement management.
External regulatory counsel are expensive resources whose time should not be wasted on scheduling logistics. The EA who manages this interface well keeps external partner time focused on substantive work.
Board and Investor Communication Coordination
Pre-Submission Investor Communication
Regulatory submission dates are material events for public pharmaceutical companies and highly anticipated milestones for private companies and their investors. The CEO’s communications around these events are carefully considered and legally reviewed.
The EA coordinates the administrative side of this communication: working with investor relations and legal to ensure the CEO’s communications calendar reflects all required disclosure-compliant communications, preparing draft press releases or statements for CEO and legal review, coordinating the logistics of any investor calls associated with submission news, and ensuring the board is informed before public disclosure.
PDUFA Date Management
The PDUFA (Prescription Drug User Fee Act) date is the FDA’s target action date for NDA/BLA review. Managing the period between NDA/BLA submission and the PDUFA date requires sustained administrative coordination: tracking FDA information requests, managing response timelines, coordinating commercial readiness activities, and preparing the board and investors for the approval decision.
The EA maintains a PDUFA date tracking system that covers all active reviews, flags information requests as they arrive, coordinates the internal response process with regulatory affairs, and prepares a running log of FDA correspondence that the CEO can review to stay current on review status.
Post-Submission Administration
Complete Response Letter Management
When the FDA issues a Complete Response Letter (CRL) rather than an approval, the pharmaceutical company must respond with additional data or information. CRL responses are high-stakes regulatory activities that require structured project management and often extensive additional clinical or manufacturing work.
The EA supports the CEO’s oversight of CRL responses by maintaining the response project timeline, tracking the completion of each required data package or manufacturing remediation, coordinating the go/no-go assessment meetings with the regulatory affairs and clinical teams, and managing the investor and board communication logistics around the CRL response strategy.
Approval Celebration and Commercial Readiness
When an approval is received, the EA coordinates the immediate administrative response: managing the press release logistics, coordinating the CEO’s media and investor communications, organizing the internal celebration communications to staff, and ensuring commercial readiness activities have the CEO’s input and sign-off where required.
This approval management function is one of the highest-visibility moments in a pharmaceutical company’s history. The CEO who navigates it with organized, coordinated communications and a clear commercial readiness posture demonstrates the organizational competence that builds long-term investor and partner confidence.
For pharma CEOs managing multiple parallel regulatory and research tracks, this research coordination guide provides a framework for maintaining pipeline visibility alongside submission management.
Global Submission Coordination
Multi-Market Regulatory Strategy
Companies pursuing global approvals face a complex multi-agency coordination challenge: EMA submissions in Europe, PMDA in Japan, Health Canada, and others in parallel with FDA activities. The EA maintains a global regulatory submission tracker that maps each agency, the relevant submission timeline, key milestone dates, and the status of agency interactions in each market.
This global view is increasingly important as pharmaceutical companies pursue international launches to maximize market potential. The CEO who has a clear, current view of global regulatory status can make better resource allocation and launch sequencing decisions.
For pharma CEOs also managing the full range of medical affairs activities that support regulatory and commercial outcomes, this medical affairs coordination guide provides a complementary framework for the stakeholder engagement and evidence generation work that surrounds regulatory submissions.
Conclusion
Regulatory submissions are the moments that define pharmaceutical companies: approval or rejection, commercial launch or delay, investor confidence or erosion. A CEO who leads these moments with strategic clarity, organized communication, and decisive engagement with regulatory agencies creates outcomes that compounding scientific success alone cannot achieve. An executive assistant who owns the administrative infrastructure of regulatory submission coordination, from timeline tracking to agency meeting preparation to board communication logistics, makes that strategic leadership possible. In an industry where regulatory outcomes shape company valuations and patient access to critical therapies, this administrative investment carries returns that belong on the same strategic ledger as pipeline investment and clinical execution.